ALX Oncology has reached a clinical trial partnership and supply agreement with Sanofi to assess evorpacept in combination with SARCLISA (isatuximab-irfc) and dexamethasone to treat patients with relapsed or refractory multiple myeloma (RRMM).
The lead product candidate of ALX Oncology, evorpacept is a new CD47 blocker that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SARCLISA (isatuximab-irfc) is Sanofi’s monoclonal antibody that has been designed to target a specific epitope on the CD38 receptor on multiple myeloma cells.
The Phase l/ll trial will investigate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept plus SARCLISA and dexamethasone in the targeted patients.
Part one of the trial will examine the dosing of evorpacept combined with standard doses of SARCLISA and dexamethasone to determine a recommended dose.
Part two will study the efficacy and safety of the therapy combination in an expanded group of RRMM patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUnder the new deal, ALX Oncology will supply evorpacept while Sanofi will provide SARCLISA for the trial.
ALX Oncology founder, president and CEO Jaume Pons said: “We are thrilled to enter this collaboration with Sanofi that has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who would benefit from novel effective treatment options.
“The combination of blocking both CD47 and CD38 has shown synergistic anti-tumour activity in preclinical studies, and this combination may re-sensitise tumours to anti-CD38 treatment or overcome anti-CD38 resistance.
“This collaboration expands our robust clinical development pipeline with evorpacept, which we intend to establish as a new and best-in-class foundational immunotherapy in both hematologic and solid tumours.”
